文献速递消化道肿瘤放疗放疗物理与技术

直肠癌近距离放疗后反应与毒性的预测因素:HERBERT研究结果

Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.
PubMed 文献 · Radiother Oncol · 2019-02-18

HERBERT研究是一项剂量探索可行性研究,评估不适合手术的老年直肠癌患者在外照射放疗后接受高剂量率腔内近距离放疗(HDREBT)加量的患者、肿瘤和剂量学参数与肿瘤反应及毒性的关联。35例完成治疗的患者中,33例可评估者中20例达到临床完全缓解,中位持续缓解时间32个月。肿瘤体积与临床完全缓解强相关(OR 1.15;p=0.005),未观察到剂量-反应相关性;近距离放疗CTV处方剂量(D90)与急性和晚期医生报告的前列腺炎相关。

要点

  • 肿瘤体积是肿瘤反应最重要的预测因素(OR 1.15;p=0.005)。
  • 本队列中未观察到剂量-反应相关性。
  • 近距离放疗CTV的D90与医生报告的急性和晚期前列腺炎相关。

核心结论

  • 肿瘤体积是肿瘤反应最重要的预测因素,近距离放疗CTV剂量越高,临床和内镜下观察到的严重前列腺炎风险越高。

研究设计与样本

  • HERBERT研究为剂量探索可行性研究,纳入38例不适合手术的T2-3N0-1直肠癌患者。
  • 方案为13次3 Gy外照射放疗后,每周3次HDREBT,每次5-8 Gy。
  • 35例完成治疗并纳入本分析。

主要发现

  • 33例可评估患者中20例达到临床完全缓解,中位持续缓解时间32个月。
  • 诊断时肿瘤体积与临床完全缓解强相关(OR 1.15;p=0.005)。
  • 本队列中未观察到剂量-反应相关性。
  • 近距离放疗CTV处方剂量(D90)与医生报告的急性和晚期前列腺炎相关。
  • CTV体积、CTV宽度及CTV内高剂量区(D1cc/D2cc)与肿瘤部位内镜评分毒性相关。

关键数值与推荐

  • 临床完全缓解评估:33例可评估患者中20例达到cCR。
  • 肿瘤体积与cCR的关联:OR 1.15;p=0.005。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The HERBERT study was a dose-finding feasibility study of a high-dose rate endorectal brachytherapy (HDREBT) boost after external beam radiotherapy (EBRT) in elderly patients with rectal cancer who were unfit for surgery. This analysis evaluates the association of patient, tumor and dosimetric parameters with tumor response and toxicity after HDREBT in definitive radiotherapy for rectal cancer. PATIENTS AND METHODS: The HERBERT study included 38 inoperable patients with T2-3N0-1 rectal cancer. Thirteen fractions of 3 Gy EBRT were followed by three weekly HDREBT applications of 5-8 Gy per fraction. Clinical and dosimetric parameters were tested for correlation with clinical complete response (cCR), sustained partial/complete response (SR), patient reported bowel symptoms, physician reported acute and late proctitis (CTCAE v3) and endoscopically scored toxicity. RESULTS: Thirty-five patients completed treatment and were included in the current analyses. Twenty of 33 evaluable patients achieved a cCR, the median duration of a sustained response was 32 months. Tumor volume at diagnosis showed a strong association with clinical complete response (OR 1.15; p = 0.005). No dose-response correlation was observed in this cohort. Prescribed dose to the brachytherapy CTV (D90) correlated with acute and late physician reported proctitis while CTV volume, CTV width and high dose regions in the CTV (D1cc/D2cc) were associated with endoscopic toxicity at the tumor site. CONCLUSION: Tumor volume is the most important predictive factor for tumor response and a higher dose to the brachytherapy CTV increases the risk of severe clinically and endoscopically observed proctitis after definitive radiotherapy in elderly patients with rectal cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Rijkmans EC, Marijnen CAM, van Triest B, et al. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. Radiother Oncol. 2019. PMID: 30935576. doi:10.1016/j.radonc.2019.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。